Tim Kelly, Ph.D., most recently served as President of Manufacturing at Asklepios Biopharmaceutical, Inc. (AskBio), which was acquired by Bayer in October 2020 for up to $4 billion. At AskBio, Tim was responsible for the manufacturing strategy and delivery of AAV-based gene therapy products for over eight clinical programs. For 15 years prior, he was with KBI Biopharma, Inc., an industry-leading contract development and manufacturing organization, where he ultimately served as President and Chief Executive Officer. As CEO of KBI Biopharma, Tim led four acquisitions and served as Chairman of Selexis SA while leading the integration of Selexis and KBI Biopharma. He began his corporate experience at Diosynth Biotechnology. Tim has overseen development and manufacturing services for over 325 biologics at all stages of development and commercialization and has supported numerous successful FDA and international regulatory inspections throughout his career. Tim earned his Ph.D. in molecular genetics and biochemistry from George State University and his BA in biology from College of the Holy Cross.
.svg)
